Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)

Hata, A; Katakami, N; Kaji, R; Yokoyama, T; Kaneda, T; Tamiya, M; Inoue, T; Kimura, H; Yano, Y; Tamura, D; Morita, S; Negoro, S

Hata, A (reprint author), Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Chuo Ku, 2-1-1 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.

CANCER, 2018; 124 (19): 3830

Abstract

BACKGROUND: Preclinical studies suggested that the addition of bevacizumab could overcome acquired resistance (AR) to epidermal growth factor receptor......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索